Amarin Corp Plc (AMRN)

[sharonc]

It seems simple doesn't it. Have you seen one fail with those parameters?

Vascepa sigificantly reduces TG, non-HDL-C, Apo B, VLDL-C, TC, and HDL-C levels from baseline relative to placebo. Just think about that. Safety issues have not occurred during real world use for 5+ years. Do you really think that a drug that safely lowers inflammatory markers doesn't reduce cardiovascular events? If that is the case then all of cardiovascular drug discovery is flawed. Fenefibrates and niacin cause other issues in the body, hence the side effects. Advisory committee grouped Vascepa in with these flawed drugs and refused to believe that Vascepa is as good as it is. Or at least that was their "concern".